MannKind (NASDAQ: MNKD)‘s stock had its “neutral” rating reaffirmed by Zacks in a research note issued on Tuesday, ARN reports. They currently have a $3.75 price target on the stock.

Zacks‘ analyst wrote, “MannKind’s fourth quarter 2012 net loss of $0.23 per share was narrower than the year-ago loss of $0.30 but wider than the Zacks Consensus Estimate of a loss of $0.18. A higher share count following the issuance of shares in Oct 2012 accounted for the lower year-over-year loss. We expect investor focus to remain on Afrezza going forward. MannKind expects to present results on Afrezza from 2 late-stage studies in mid-August this year. The company plans to resubmit the NDA for Afrezza in late September or early October with a final decision expected in Apr/Mar 2014. However, we remain concerned about the company’s over dependence on Afrezza. We see limited upside from current levels and retain our Neutral stance on the stock. “

A number of other analysts have also recently weighed in on MNKD. Analysts at Bank of America reiterated a “buy” rating on shares of MannKind in a research note to investors on Wednesday, March 27th. They now have a $5.00 price target on the stock, up previously from $3.00. Analysts at Wells Fargo reiterated a “market perform” rating on shares of MannKind in a research note to investors on Monday, March 11th.

Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. MannKind presently has an average rating of “Hold” and a consensus target price of $4.92.

MannKind (NASDAQ: MNKD) traded up 6.78% on Tuesday, hitting $3.7799. MannKind has a 1-year low of $1.57 and a 1-year high of $3.67. The stock’s 50-day moving average is currently $2.95. The company’s market cap is $1.047 billion.

MannKind (NASDAQ: MNKD) last posted its quarterly earnings results on Monday, February 11th. The company reported ($0.23) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.19) by $0.04. During the same quarter last year, the company posted ($0.30) earnings per share. Analysts expect that MannKind will post $-0.49 EPS for the current fiscal year.

MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.

http://www.dailypolitical.com/finance/stock-market/mannkind-stock-rating-reaffirmed-by-zacks-mnkd-2.htm

By the way Zacks has a buy on Biodel.Go figure.

http://www.zacks.com/stock/news/95995/pipeline-progress-at-biodel